 Clifford Hudis |  Mark Einstein |  Tony Greco |  James Berenson |  Edward Ambinder |
Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
CLIFFORD HUDIS, Memorial Sloan-Kettering Cancer Center, New York
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York
Clifford Hudis of the Memorial Sloan-Kettering Cancer Center in New York presented data to support the idea that HER2 is still a useful target after progression on trastuzumab. One of the drugs he focused on was 17AAG, an Hsp90 inhibitor.
Therapeutic Vaccination For Cervical Neoplasia
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
MARK EINSTEIN, Montefiore Medical Center, Albert Einstein College of Medicine, New York
Could vaccination have a therapeutic role in the treatment of cervical cancer? Mark Einstein, from the Montefiore Medical Center in New York, presented data on a vaccination for high-grade cervical intraepithelial neoplasia.
New Drugs in Both Non- Small Cell Lung Cancer and Small Cell Lung Cancer
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
Tony GRECO, Sarah Cannon Cancer Center, Nashville
Tony Greco of the Sarah Cannon Cancer Center in Nashville explained some new drugs for treating lung cancer. One is a new alkylating agent, while the other is albumin-bound paclitaxel.
Multiple Myeloma: Could Arsenic Trioxide Have a Role in Treatment?
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
JAMES BERENSON, Institute for Myeloma and Bone Cancer Research, California
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York
A study presented by James Berenson, of the Institute of Myeloma and Bone Cancer Research in California, suggests that arsenic trioxide is another useful option in relapsed or refractory multiple myeloma.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
